• Mashup Score: 9
    Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer - 3 year(s) ago

    Basel, 27 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer…

    Source: www.roche.com
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of teamoncology
      teamoncology

      Atezolizumab FDA indication in 1st line metastatic triple-negative breast cancer will cease due to the treatment landscape change by KEYNOTE-522. Surprised but not surprised. #bcsm https://t.co/0VeFXHEyVD

    • Profile photo of mzbaptista
      mzbaptista

      Happening Now! @Roche decided to voluntarily withdraw the US accelerated approval for Atezolizumab in combination w/nab-paclitaxel for PD-L1+ unresec LA/mTNBC 👉This decision only impacts the US #bcsm #ImmunoOnc #Immunotherapy #breastcancer #mustread https://t.co/ryaBwH4oeJ

    • Profile photo of ESchattner
      ESchattner

      Roche "has made the decision" to withdraw the U.S. accelerated approval for Tecentriq (atezolizumab) in comb. w/ chemo (Abraxane) for people w/ advanced or metastatic #PDL-1+ triple negative breast cancer, @Roche - https://t.co/GkfQlLP5y9 #IO #mbc #TNBC #FDAapprovals

  • Mashup Score: 0
    Events | - 3 year(s) ago

    Project Livin’ Label is a new educational initiative that aims to foster broad understanding of the associated oncology product label and increase awareness of recent oncology drug FDA approvals in the cancer community.Using oncology product labeling as a roadmap, the FDA’s Oncology Center of Excellence (OCE) will guide discussions between an FDA reviewer, a clinical trial investigator, a…

    Source: bit.ly
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of FDAOncology
      FDAOncology

      💻 Register and watch the latest #FDAOncology Project Livin’ Label! Hear all about the backstory of dara CyBorD for amyloidosis. #ProjectLivinLabel #druglabels #FDAapprovals https://t.co/m2Mp49Jjse https://t.co/EP4mU7X7T3

  • Mashup Score: 1
    Weekly Roundup: March 29- April 2, 2021 - 3 year(s) ago

    ICYMI, some of this week’s featured content includes what FDA approvals to watch for in April, trending skin care, navigating the match process, plus more.

    Source: Dermatology Times
    Categories: Dermatology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DermTimesNow
      DermTimesNow

      ICYMI, some of this week’s featured content includes what #FDAapprovals to watch for in April, trending #skincare, navigating the #match process, plus more. https://t.co/hKQFzYVX1T https://t.co/It0adp4VRt

  • Mashup Score: 0
    Weekly Roundup: February 8-12, 2021 - 3 year(s) ago

    In case you missed it, some of this week’s featured content includes the latest FDA approvals, newly published phase 3 data for tirbanibulin, oxytocin and its effect on skin aging, plus more.

    Source: Dermatology Times
    Categories: Dermatology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DermTimesNow
      DermTimesNow

      In case you missed it, some of this week’s featured content includes the latest #FDAapprovals, newly published phase 3 data for tirbanibulin, #oxytocin and its effect on #skinaging, plus more. https://t.co/JkTQCqS1uS https://t.co/tu0pKnlTvP

  • Mashup Score: 0
    Weekly Roundup: February 1-5, 2021 - 3 year(s) ago

    In case you missed it, some of this week’s featured content includes a new podcast episode on the popularity of TikTok for dermatologists, FDA approvals for Soliton’s RAP device for cellulite and Galderma’s Restylane Defyne for chin augmentation, enrollment commencement for a food supplement and skin inflammation study, plus more.

    Source: Dermatology Times
    Categories: Dermatology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DermTimesNow
      DermTimesNow

      In case you missed it, some of this week’s featured content includes a new #podcast episode, #FDAapprovals for Soliton’s RAP device for #cellulite and Galderma’s Restylane Defyne for #chinaugmentation, plus more. https://t.co/lgqXfKY7lD https://t.co/6K7jFU9dLy

  • Mashup Score: 0
    DermWireTV: 2020 in Review - Practical Dermatology - 3 year(s) ago

    Crisaborole ointment became the first and only steroid-free, topical prescription medication for mild to moderate AD in patients as young as three months of age. Ustekinumab is  approved for pediatric patients with moderate to severe plaque…

    Source: Practical Dermatology
    Categories: Dermatology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Practical_Derm
      Practical_Derm

      Don't miss this DermWire TV. From new #acne treatments to label extensions for #atopic #dermatitis and #psoriasis, watch now for a review of how the field has grown. https://t.co/dUbLxbi8e7 #yearinreview #dermatology #DermWireTV #acne #psoriasis #eczema #rosacea #FDAapprovals https://t.co/755s7PmwgI